Allison Naleway to Respiratory Syncytial Virus, Human
This is a "connection" page, showing publications Allison Naleway has written about Respiratory Syncytial Virus, Human.
Connection Strength
0.061
-
Respiratory syncytial virus (RSV) vaccine effectiveness against RSV-associated hospitalisations and emergency department encounters among adults aged 60 years and older in the USA, October, 2023, to March, 2024: a test-negative design analysis. Lancet. 2024 Oct 19; 404(10462):1547-1559.
Score: 0.061